Australian Pharmaceuticals & Biotech Most Popular Stocks

CSL

Market Cap: AU$73.4b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Mesoblast

Market Cap: AU$3.2b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Telix Pharmaceuticals

Market Cap: AU$3.1b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.

Neuren Pharmaceuticals

Market Cap: AU$1.7b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Clarity Pharmaceuticals

Market Cap: AU$1.1b

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

PYC Therapeutics

Market Cap: AU$989.7m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Opthea

Market Cap: AU$738.8m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Immutep

Market Cap: AU$552.6m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Clinuvel Pharmaceuticals

Market Cap: AU$538.2m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Racura Oncology

Market Cap: AU$408.4m

Operates as a Phase 3 clinical biopharmaceutical company for cancer care.

Dimerix

Market Cap: AU$303.2m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Orthocell

Market Cap: AU$255.0m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

Aroa Biosurgery

Market Cap: AU$241.8m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Botanix Pharmaceuticals

Market Cap: AU$226.6m

Operates as a commercial dermatology company in Australia and the United States.

Mayne Pharma Group

Market Cap: AU$216.9m

A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Starpharma Holdings

Market Cap: AU$199.5m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.

Nyrada

Market Cap: AU$196.0m

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Tetratherix

Market Cap: AU$189.9m

Engages in biomaterial and regenerative medicine business in Australia and internationally.

Recce Pharmaceuticals

Market Cap: AU$170.6m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

Actinogen Medical

Market Cap: AU$145.4m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Vita Life Sciences

Market Cap: AU$142.6m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

Paradigm Biopharmaceuticals

Market Cap: AU$132.3m

Engages in the research and development of therapeutic products for human use in Australia.

Arovella Therapeutics

Market Cap: AU$111.7m

A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.

Vitrafy Life Sciences

Market Cap: AU$109.2m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

Island Pharmaceuticals

Market Cap: AU$103.6m

A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.

LTR Pharma

Market Cap: AU$100.0m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Trajan Group Holdings

Market Cap: AU$99.9m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

Cynata Therapeutics

Market Cap: AU$95.5m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Alterity Therapeutics

Market Cap: AU$87.0m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Imugene

Market Cap: AU$83.6m

A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Cleo Diagnostics

Market Cap: AU$82.8m

A biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.

Radiopharm Theranostics

Market Cap: AU$70.9m

A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Prescient Therapeutics

Market Cap: AU$68.3m

A clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia.

Neurizon Therapeutics

Market Cap: AU$67.5m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Proteomics International Laboratories

Market Cap: AU$66.1m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Amplia Therapeutics

Market Cap: AU$61.6m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.